Long-term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion.

Takeda, Haruhiko; Nishijima, Norihiro; Nasu, Akihiro; Komekado, Hideyuki; Kita, Ryuichi; Kimura, Toru; Kudo, Masatoshi; Osaki, Yukio

Takeda, Haruhiko; Nishijima, Norihiro; Nasu, Akihiro; Komekado, Hideyuki; Kita, Ryuichi; Kimura, Toru; Kudo, Masatoshi; Osaki, Yukio.

Afiliación

Takeda H; Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto.
Nishijima N; Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka.
Nasu A; Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka.
Komekado H; Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka.
Kita R; Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka.
Kimura T; Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka.
Kudo M; Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka.
Osaki Y; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.

Hepatol Res ; 49(5): 594-599, 2019 May.

Article en En | MEDLINE | ID: mdl-30499247

Palabras clave

hepatocellular carcinoma; intratumoral vascularity; lenvatinib; modified RECIST; molecular targeting therapy; response

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Hepatol Res Año: 2019 Tipo del documento: Article Pais de publicación: Países Bajos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google